cdk6/cyclind2

Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

Palbociclib-D8 is the 2H-labeled form of Palbociclib. Palbociclib (T1785) is an orally active CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM). Palbociclib (T1785) has anti-tumor activity and is used in research for estrogen receptor-positive and HER2-negative breast cancer.

Palbociclib Isethionate (PD 0332991 isethionate) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.

GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4/6, exhibiting IC50 values of 1.5 μM for CDK4/cyclin D1, 5.6 μM for CDK6/cyclin D1, and 25 μM for Cdk5/p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2].

Palbociclib hydrochloride (pabociclib hydrochloride) is the salt form of Palbociclib, a selective and orally available CDK4 and CDK6 inhibitor with anti-tumor proliferative activity for use in breast and hepatocellular carcinoma.

Palbociclib (PD 0332991) dihydrochloride is an orally active, selective inhibitor of CDK4 (IC50: 11 nM) and CDK6 (IC50: 16 nM), exhibiting anti-proliferative activity and inducing cell cycle arrest in HR-positive and HER2-negative breast cancers and hepatocellular carcinoma studies.

Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively. This compound demonstrates potent anti-proliferative effects and induces cell cycle arrest in cancer cells, applicable in research concerning HR-positive, HER2-negative breast cancer, and hepatocellular carcinoma [1] [3] [4].